Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Timothy Dekker

Sports Medicine Rochester, MI Medical Doctor

NPI 1538516646 CMS profile 4212931

1135 W University Dr Ste 450, Rochester, MI 48307

Open in the dashboard

General payments

$7,017

51 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Dekker of Rochester, MI is reported in the CMS Open Payments database as having received $7,017 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,162 6
2024 General $409 2
2023 General $1,858 21
2022 General $2,388 21
2021 General $1,200 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Dekker
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Timothy Dekker were reported at $1,162. Among 1,257 Sports Medicine profiles paid that year, the median was $114 and the middle half received between $39 and $293.

Show as a table
Year Timothy Dekker Sports Medicine median Middle half National median
2019 $0 $119 $35–$362 $163
2020 $0 $77 $24–$275 $114
2021 $1,200 $104 $28–$340 $132
2022 $2,388 $94 $31–$272 $149
2023 $1,858 $91 $34–$271 $160
2024 $409 $126 $38–$294 $164
2025 $1,162 $114 $39–$293 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Pinnacle, Inc $3,035 10 payments
  2. Pacira Pharmaceuticals Incorporated $2,352 19 payments
  3. Arthrex, Inc. $1,532 18 payments
  4. ConvaTec Inc. $29 1 payment
  5. Aroa Biosurgery Incorporated $28 1 payment
  6. Stimwave Technologies Incorporated $25 1 payment
  7. Gilead Sciences, Inc. $17 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $4,650 13 payments
  2. Education $1,200 1 payment
  3. Food and Beverage $1,168 37 payments
Products named General payments · program years 2021–2025
  1. Iovera $2,352 19 payments
  2. Zilretta $40 3 payments
  3. INNOVAMATRIX AC $29 1 payment
  4. StimQ Receiver Stimulator Kit Channel A US w/Receiver $25 1 payment
  5. StimQ Freedom-4A Receiver Kit Channel A US w/ Receiver $25 1 payment
  6. StimQ Freedom-8A Receiver Kit Channel A US w/ Receiver $25 1 payment
  7. Freedom-4A Receiver Kit Channel A US w/ Receiver $25 1 payment
  8. Freedom-8A Receiver Kit Channel A US w/ Receiver $25 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

195

Median for Family Practice: 1,826

Drug cost

$1,319

Median for Family Practice: $120,094

Branded share of claims

0%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Diclofenac Sodium Generic 114 $997
Baclofen Generic 12 $138
Prednisone Generic 53 $105
Gabapentin Generic 16 $79

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 86 billing codes

Paid by Medicare

$118,173

Of which drugs: $6,543

Medicare patients

717

Average age 71

Services billed

3,186

466 women, 251 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 56%
Ischemic heart disease 29%
Diabetes 26%
Depression 22%
Chronic kidney disease 18%
COPD 14%
Atrial fibrillation 13%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 21 98 $5,628
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 39 285 $192
Injection, methylprednisolone sodium succinate, 5 mg J2919 Office 15 295 $60
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme J7620 Office 14 20 $3

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record